ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO1072

Real-World Effectiveness and Tolerability of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Treatment-Experienced (TE) People with HIV with a History of CKD

Session Information

Category: CKD (Non-Dialysis)

  • 2302 CKD (Non-Dialysis): Clinical, Outcomes, and Trials


  • Rieke, Ansgar, Gemeinschaftsklinikum Mittelrhein, Kemperhof Koblenz, Koblenz, Germany
  • De Wet, Joss, Spectrum Health, Vancouver, British Columbia, Canada
  • Esposito, Vincenzo, Infectious Diseases and Gender Medicine Unit, Cotugno Hospital, AO dei Colli, Naples, Italy
  • Silva-Klug, Ana, HIV and STD Unit (Infectious Disease Service), Hospital Universitari de Bellvitge-Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
  • Levy, Itzchak, Infectious Disease Unit, Sheba Medical Center, Tel Hashomer, Israel
  • Lambert, John S., Mater Misericordiae University Hospital, Dublin, Ireland
  • Boffito, Marta, HIV Department, Chelsea and Westminster Hospital Foundation Trust, London, United Kingdom
  • van Welzen, Berend, Department of Infectious Diseases, University Medical Centre Utrecht, Utrecht, Netherlands
  • Rogers, Rachel, Gilead Sciences, Inc., Foster City, California, United States
  • Unger, Nathan, Gilead Sciences, Inc., Foster City, California, United States
  • Cassidy, Tali, Gilead Sciences, Stockley Park, United Kingdom
  • Harrison, Rebecca, Gilead Sciences, Stockley Park, United Kingdom
  • Katlama, Christine, Infectious Diseases Department, Sorbonne University, Hôpital Pitié-Salpêtrière, Paris, France

TAF-containing regimens, eg B/F/TAF, are approved in the US in people with an estimated CrCl ≥30 mL/min and have demonstrated comparable long-term renal safety vs non–tenofovir-based regimens. No proximal renal tubulopathies have been reported in 26 TAF trials or in a trial rechallenging those with history of tubulopathy on tenofovir disoproxil fumarate.


We investigated the renal safety profile and efficacy of B/F/TAF in the BICSTaR study, in which 963 TE participants with HIV switched from current antiretroviral therapy (ART) to B/F/TAF.


Of 843 participants with baseline (BL) eGFR data available, 90 had CKD (MDRD eGFR <60 mL/min/1.73 m2), 83% were male and 85% were non-Black. More participants with vs without BL CKD were >50 yrs old (79% vs 43%; P<0.001), had ≥1 cardiovascular condition (54% vs 20%; P<0.001), diabetes mellitus (12% vs 6%; P=0.029) and hypertension (44% vs 16%; P<0.001). Those with vs without BL CKD had longer prior exposure to ART and time from diagnosis to B/F/TAF initiation (Table).

Drug-related (DR) AEs were reported in 16% of people with BL CKD vs 15% in those without. A single DR renal AE (RAE) was reported in 1 person with BL CKD (proteinuria, drug continued); there were no DR RAE discontinuations or serious DR RAEs. Median eGFR was stable through 24 months for people with BL CKD (Fig.).


B/F/TAF was effective and safe with respect to renal outcomes in this real-world study in TE people with HIV and CKD switching to B/F/TAF, supporting use of TAF-based regimens in people with eGFR <60 mL/min/1.73 m2.